Ocular Changes in People Using Tirzepatide or Semaglutide
Official title: Evaluation of Optic Nerve Head, Retinal Changes, and Choroidal Blood Flow in Patients With Diabetes and Obesity Using Tirzepatide or Semaglutide
Run by Istanbul University · NCT07924618 · Data updated 2026-11-12
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Istanbul University Academic / other |
| Locations | 1 site (Istanbul, Istanbul) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | September 17, 2027 |
| Study ends | September 17, 2027 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07924618 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with obesity who are receiving semaglutide or tirzepatide as part of routine care, with or without type 2 diabetes, and able to complete ophthalmologic follow-up.
✕Probably not a fit
Individuals unable to attend follow-up ophthalmologic exams or who do not experience any ocular changes may not receive direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational cohort follows adults with obesity, with or without type 2 diabetes, who are treated with semaglutide or tirzepatide. Participants undergo eye exams at baseline and up to 18 months later, using OCT and OCT-A to measure retina and choroid structure and microvasculature, along with visual acuity and intraocular pressure. The study aims to identify any treatment-related ocular changes by comparing baseline and follow-up measurements across four groups based on diabetes status and medication. Data will be collected from Istanbul University and Istanbul Faculty of Medicine. No intervention beyond standard care is performed, and there is no randomization or blinding involved.
Why it matters
Potential benefit: If changes are detected, findings could help inform monitoring strategies for eye health in patients treated with these medications.
How similar studies have gone: Few similar observational studies exist in this area; this study will provide initial real-world data on ocular effects of these medications.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Diagnosis of obesity * Receiving semaglutide or tirzepatide as part of routine clinical care * Participants with or without type 2 diabetes mellitus * Availability for baseline and follow-up ophthalmologic examinations Exclusion Criteria: * Age under 18 years * Not receiving semaglutide or tirzepatide * Inability to complete the required ophthalmologic examinations or imaging assessments
Where it's running
-
Istanbul University, Istanbul Faculty of Medicine
Istanbul, Istanbul, Turkey (Türkiye) Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Once-daily ASC30 to See if it helps adults with obesity or overweight and Type 2 diabetes
This study tests three daily doses of ASC30 against placebo in adults who are overweight or obese and have Type 2 diabetes to see if it helps with weight loss and safety over time.
-
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD
This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.
-
Structured management of adult cardiovascular risk factors in outpatient care
This project will try a structured clinic approach to managing blood pressure, cholesterol, diabetes, and weight in adults with cardiovascular risk factors to see if it improves risk control and outcomes.
-
Using imaging to predict weight loss success after bariatric surgery
This study is testing if looking at CT scans of belly fat can help predict how much weight people will lose and if their type 2 diabetes will improve after bariatric surgery.
-
Understanding chronic kidney disease in Sub-Saharan Africa
This study is trying to understand how common chronic kidney disease is in Sub-Saharan Africa and what factors might be causing it by looking at the health and lifestyle of adults in the Bagamoyo district.
-
Investigating nutritional and environmental factors in elderly health
This study is trying to find out how nutrition and the environment affect the health of older people living in Nanshan to help prevent diseases like high blood pressure and diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.